Evolution of the Average Target: DexCom, Inc.

Evolution of the Target Price: DexCom, Inc.

Changes in Analyst Recommendations: DexCom, Inc.

93b22fbc58b08e03c1962399.13-L4RjrsuhH7SDI8VQ97Z1tB2qgxWBVclSRHv2ESPI.hz7qjHaS6qESq0i5gTl7hLA0MUfkjwUzMwvAXJb8fbqbGuTQLNv9uROGdQ~85a44ba852e7a395831194493b876476
06-10 TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating MT
06-10 Analyst recommendations: Nike, Pfizer, Hewlett Packard, Intel, The Trade Desk… Zonebourse
06-09 Raymond James Adjusts Price Target on DexCom to $91 From $81, Maintains Strong Buy Rating MT
06-08 Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating MT
06-05 Stifel Adjusts Price Target on DexCom to $90 From $85, Maintains Buy Rating MT
05-28 Citigroup Adjusts Price Target on DexCom to $84 From $79, Maintains Buy Rating MT
05-27 Goldman Sachs Adjusts Price Target on DexCom to $85 From $80, Maintains Buy Rating MT
05-18 BofA Securities Adjusts Price Target on DexCom to $80 From $100 MT
05-15 DexCom Long-Range Plan Establishes Respectable Base Case, RBC Says MT
05-15 Barclays Cuts DexCom Price Target to $64 From $67, Maintains Underweight Rating MT
05-15 Canaccord Genuity Adjusts DexCom Price Target to $82 From $100, Maintains Buy Rating MT
05-12 Benchmark Initiates DexCom at Buy With $77 Price Target MT
05-06 Argus Adjusts Price Target on DexCom to $86 From $90 MT
05-01 JPMorgan Adjusts DexCom Price Target to $65 From $75 MT
05-01 Analyst recommendations: Apple, ConocoPhillips, Stryker Corporation, Parker-Hannifin, Equinix Zonebourse
05-01 Barclays Adjusts Price Target on DexCom to $67 From $72, Maintains Underweight Rating MT
05-01 Baird Adjusts Price Target on DexCom to $80 From $87, Maintains Outperform Rating MT
05-01 Leerink Partners Adjusts Price Target on DexCom to $80 From $95, Maintains Outperform Rating MT
05-01 Bernstein Adjusts Price Target on DexCom to $77 From $83, Maintains Outperform Rating MT
05-01 Mizuho Adjusts Price Target on DexCom to $75 From $90, Maintains Outperform Rating MT
05-01 Raymond James Adjusts Price Target on DexCom to $81 From $83, Maintains Strong Buy Rating MT
05-01 Canaccord Genuity Adjusts Price Target on DexCom to $100 From $95, Maintains Buy Rating MT
05-01 Goldman Sachs Adjusts Price Target on DexCom to $80 From $82, Maintains Buy Rating MT
05-01 TD Cowen Adjusts Price Target on DexCom to $75 From $84, Maintains Buy Rating MT
05-01 Citigroup Adjusts Price Target on DexCom to $79 From $84, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+13.24%
+31.54%
+22.84%
+24.66%
+17.13%
+22.63%
+39.98%
+8.42%
+28.32%
+23.43%
Average +23.22%
Weighted average by Cap. +25.05%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
75.25USD
Average target price
84.67USD
Spread / Average Target
+12.51%
High Price Target
112.00USD
Spread / Highest target
+48.84%
Low Price Target
65.00USD
Spread / Lowest Target
-13.62%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

TD Cowen
Raymond James
Mizuho Securities
Stifel Nicolaus
Citigroup
Goldman Sachs
BofA Securities
Barclays
Canaccord Genuity
Benchmark Company
Argus
JPMorgan Chase
Baird
Leerink Partners
Bernstein
BTIG
Evercore ISI
Truist Securities
Wells Fargo Securities
Morgan Stanley
Rothschild & Co Redburn
UBS
Piper Sandler
RBC Capital Markets
Wolfe Research
Oppenheimer
Jefferies & Co.
Redburn Atlantic
Nephron Research
Cowen
SVB Leerink
Haywood Securities
Berenberg Bank
Guggenheim
Atlantic Equities
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
75.25USD
Average target price
84.67USD
Spread / Average Target
+12.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DXCM Stock
  4. Consensus DexCom, Inc.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!